Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist.
about
Gas6 regulates mesangial cell proliferation through Axl in experimental glomerulonephritisGenomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridolRoscovitine in cancer and other diseasescPLA2-interacting protein, PLIP, causes apoptosis and decreases G1 phase in mesangial cellsThe anti-apoptosis protein, survivin, mediates gastric epithelial cell cytoprotection against ethanol-induced injury via activation of the p34(cdc2) cyclin-dependent kinaseProtein inhibitor of activated STAT, PIASy regulates α-smooth muscle actin expression by interacting with E12 in mesangial cellsCell cycle regulatory proteins in renal disease: role in hypertrophy, proliferation, and apoptosis.TGF-{beta}1 protects against mesangial cell apoptosis via induction of autophagyPharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteinsAntifibrotic effects of roscovitine in normal and scleroderma fibroblasts.DNA damage is a novel response to sublytic complement C5b-9-induced injury in podocytes.Mesangial cell proliferation inhibitors for the treatment of proliferative glomerular disease.CDK inhibitors in clinical development for the treatment of cancer.Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functionsIdentification of kinase inhibitors that target transcription initiation by RNA polymerase IIExpression of GSK-3β in renal allograft tissue and its significance in pathogenesis of chronic allograft dysfunction.Cdk inhibitory nucleoside analogs prevent transcription from viral genomes.Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs.The cell cycle and acute kidney injury.CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury.Cell cycle control in the kidney.Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy.Roscovitine, a cyclin-dependent kinase inhibitor, prevents replication of varicella-zoster virus.Reduction of ciliary length through pharmacologic or genetic inhibition of CDK5 attenuates polycystic kidney disease in a model of nephronophthisis.Gas6 induces mesangial cell proliferation via latent transcription factor STAT3.Growth arrest-specific gene 6 is involved in glomerular hypertrophy in the early stage of diabetic nephropathy.Mycophenolate mofetil and roscovitine decrease cyclin expression and increase p27(kip1) expression in anti Thy1 mesangial proliferative nephritis.Effects of the cyclin-dependent kinase inhibitor R-roscovitine on eosinophil survival and clearance.Role of differential and cell type-specific expression of cell cycle regulatory proteins in mediating progressive glomerular injury in human IgA nephropathy.Casein kinase 1ε and 1α as novel players in polycystic kidney disease and mechanistic targets for (R)-roscovitine and (S)-CR8.The regulation of mesangial cell proliferation.Therapeutics in renal disease: the road ahead for antiproliferative targets.Treatment with a cyclin-dependent kinase inhibitor, seliciclib, is effective in reducing glomerular macrophage numbers and the severity of established experimental glomerulonephritis.A Simple Isomerization of the Purine Scaffold of a Kinase Inhibitor, Roscovitine, Affords a Four- to Seven-Fold Enhancement of Its Affinity for Four CDKs. Could This Be Traced Back to Conjugation-Induced Stiffenings/Loosenings of Rotational Barriers?
P2860
Q24672961-DF9915A8-EC44-4407-8795-E509BBAE24FEQ24805832-98D88F3E-0DAC-4B8F-BDBD-C8AFF0010A02Q26799874-C4849186-78C5-4F89-A69E-903855486DFBQ28564835-E6E53200-BABC-4BEA-A68C-55C30218F702Q28574978-4E75EDE0-E7EF-4889-9C5E-CB398D9D7482Q28729019-682DF5DE-8376-41D7-8157-766A1A7A6F3DQ33883556-80F10605-7EA7-4015-B336-51F17BF9D84DQ34333868-2F87F732-2F23-4A61-8D1C-9449DE81E7C6Q34343774-F9177435-70E7-4E48-8A35-EA35F3D9B84FQ34489708-8575D52A-543E-4CBB-8043-83604D8B3910Q34967711-451223B6-2B88-44D6-9E15-ED91BB8F1BABQ34993147-3DBD53CF-B0EB-4BFD-97E4-008E054C5CD0Q35143997-F5615519-3142-4FD1-AC02-9EE3ACE9A5BEQ35549264-6F66208D-E212-41F1-9A5E-68A62F07CAB4Q35640132-0583FBF8-8BD1-4E6A-9013-C40C2A4D60E0Q35866243-5878DCE6-5D15-4E78-B83B-3DE406983D1FQ36296415-A70B1052-779A-44C2-9666-0A28E975F664Q36349640-415196B5-AB61-449A-A622-212F376A79CFQ36709312-30E537C2-25FB-4737-9080-3F1976FD2EDCQ36716750-FBF4B3AD-4195-47FD-B53E-9043801587D2Q37436067-F1BEA0E2-3CFF-43A5-B872-37181A6F0BEAQ37575488-9885B08C-40C1-43E1-BB99-4A2D64C420D5Q38299707-810CCE1A-3216-415F-BB18-58A381BFAF96Q40269064-774B4320-2AFD-4AF8-ABDA-3576CE7637EBQ40584589-B6950B84-1C02-4BE9-BE55-318AF3331C73Q41584686-87F1FD57-00BE-4AA8-8ACE-73C22F9A8D12Q43730447-D373A226-C483-4B77-8DB8-4C4E3FD4F295Q44367172-2F801E75-DB3E-448F-A6E2-13DF752CDE62Q45227447-52ABA3D0-77F9-4AC4-9FBE-EBB6EB3390C7Q46092022-67130C17-FA60-407C-81C8-C22CFACFFB20Q47314961-8953025D-7DC1-47D4-B950-5585BC24FA2EQ52656392-BF29A769-CB5C-4B46-9650-C59524196749Q53481596-D6DD46DD-9D44-4FC6-9DA7-F053E89C62EDQ53644742-7A9BF6FB-38A7-4A9C-9476-FFCFEBE5893FQ54594584-BF555DB8-2807-49B9-BA0E-49204E760993Q58736257-D39B0FB1-2992-4212-9790-8ADFB31690F7
P2860
Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Direct in vivo inhibition of t ...... n-dependent kinase antagonist.
@en
Direct in vivo inhibition of t ...... n-dependent kinase antagonist.
@nl
type
label
Direct in vivo inhibition of t ...... n-dependent kinase antagonist.
@en
Direct in vivo inhibition of t ...... n-dependent kinase antagonist.
@nl
prefLabel
Direct in vivo inhibition of t ...... n-dependent kinase antagonist.
@en
Direct in vivo inhibition of t ...... n-dependent kinase antagonist.
@nl
P2093
P2860
P356
P1476
Direct in vivo inhibition of t ...... n-dependent kinase antagonist.
@en
P2093
P2860
P304
P356
10.1172/JCI119793
P407
P577
1997-11-01T00:00:00Z